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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is a highly lethal cancer that contains cellular and
functional heterogeneity. Previously, we enriched a subpopulation of highly tumorigenic head and neck cancer
initiating cells (HN-CICs) from HNSCC. However, the molecular mechanisms by which to govern the characteristics
of HN-CICs remain unclear. GRP78, a stress-inducible endoplasmic reticulum chaperone, has been reported to play
a crucial role in the maintenance of embryonic stem cells, but the role of GRP78 in CICs has not been elucidated.
Results: Initially, we recognized GRP78 as a putative candidate on mediating the stemness and tumorigenic
properties of HN-CICs by differential systemic analyses. Subsequently, cells with GRP78 anchored at the plasma
membrane (
memGRP78
+) exerted cancer stemness properties of self-renewal, differentiation and radioresistance. Of
note, xenotransplantation assay indicated merely 100
memGRP78
+ HNSCCs resulted in tumor growth. Moreover,
knockdown of GRP78 significantly reduced the self-renewal ability, side population cells and expression of
stemness genes, but inversely promoted cell differentiation and apoptosis in HN-CICs. Targeting GRP78 also
lessened tumorigenicity of HN-CICs both in vitro and in vivo. Clinically, co-expression of GRP78 and Nanog
predicted the worse survival prognosis of HNSCC patients by immunohistochemical analyses. Finally, depletion of
GRP78 in HN-CICs induced the expression of Bax, Caspase 3, and PTEN.
Conclusions: In summary,
memGRP78 should be a novel surface marker for isolation of HN-CICs, and targeting
GRP78 signaling might be a potential therapeutic strategy for HNSCC through eliminating HN-CICs.
Background
Head and neck squamous cell carcinoma (HNSCC)
ranks the third most common cancer in developing
nations as well as the sixth worldwide [1]. In spite of
improvements in the diagnosis and management of
HNSCC, long-term survival rates have improved only
marginally over the past decade [2]. Therefore, re-evalu-
ating our current knowledge on HNSCC and developing
novel therapeutic strategies is crucial. The reasonable
explanation of this phenomenon is the existence of a
rare subpopulation of cells within tumor that exhibit
self-renewal capacity-the purported cancer stem cells
(CSCs) or cancer initiating cells (CICs) [3,4]. CICs have
been known to have the capacity to promote tumor
regeneration and metastasis, and contribute to radio-
resistance and chemo-resistance [5,6]. Experimental evi-
dence for the existence of CICs has been reported for
several tumor types, including brain, breast, colon, pros-
tate, lung and HNSCC [7-12]. We previously demon-
strated a subpopulation of HNSCCs displaying the
characteristics of CICs using sphere formation assay
[13]. However, the molecular characteristics and regula-
tory mechanisms that mediate HN-CICs properties
remain unidentified. Therefore, uncovering key genes
responsible for the maintenance of self-renewal and
tumorigenicity in the HN-CICs is an imperative
approach for new drug development.
* Correspondence: jflo@ym.edu.tw; ccyu@csmu.edu.tw
† Contributed equally
1Institute of Oral Biology, National Yang-Ming University, Taipei, Taiwan
9Institute of Oral Biology and Biomaterial Science, Chung Shan Medical
University, Taichung, Taiwan
Full list of author information is available at the end of the article
Wu et al. Molecular Cancer 2010, 9:283
http://www.molecular-cancer.com/content/9/1/283
© 2010 Wu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.GRP78/BiP/HSPA5, a central mediator of endoplasmic
reticulum (ER) homeostasis, involves in the regulation of
a variety of biological functions including protein fold-
ing, ER calcium binding, controlling of the activation of
transmembrane ER stress sensors and cell survival [14].
Although the major subcellular localization of GRP78 is
ER, GRP78 has been reported to be anchored at the
plasma membrane [15]. It is well documented that
GRP78 plays a crucial role in both stem cell and cancer
biology. For instance, GRP78 is required for survival of
embryonic stem cell precursors and is also highly
expressed in hematopoietic stem cells [16]. Additionally,
GRP78 is a mediator for tumor proliferation and metas-
tasis, and confers resistance after chemotherapy and
radiotherapy [15,17]. GRP78 is overexpressed in many
tumor cells, including lung, breast, stomach, prostate,
colon, and liver cancer [17,18]. In contrast, mice redu-
cing GRP78 expression suppresses tumor development
and promotes apoptosis [19]. Moreover, recent data
point out that GRP78 regulates multiple malignant phe-
notypes of HNSCCs [20-22]. In addition, GRP78 is sig-
nificantly up-regulated in breast disseminated tumor
cells (DTC), which share the similar biological proper-
ties of CICs [23]. However, the role of GRP78 in CICs
has never been determined. Based on these findings, it
is worthy to investigate the importance of GRP78 in
HNSCC tumorigenesis and in the maintenance cancer
stemness properties of HN-CICs if GRP78 is preferen-
tially overexpressed in CICs.
In the current study, we first identified GRP78/
memGRP78 expression was significantly increased in iso-
lated HN-CICs, and
memGRP78
+ cells posses higher
tumorigenic potential and stemness properties. Conse-
quently, we determined that a novel molecular pathway,
GRP78 signaling, is linked to HN-CICs self-renewal and
tumorigenicity. Overall, our studies provide evidence
that inhibiting GRP78 signaling should be considered
for further exploitation on therapeutic development for
HNSCC.
Results
Elevation of GRP78 expression in Head and Neck Cancer
Initiating Cells (HN-CICs)
Previously, we have demonstrated the existence of HN-
CICs [13]. To further elucidate the molecular mechan-
isms by which to mediate the self-renewal ability and
tumorigenicity of HN-CICs, molecular targets specifi-
cally expressed in HN-CICs were to be identified. The
differential expression profile between HN-CICs and
HNSCCs was examined by either systemic transcip-
tome analysis or two-dimensional differential gel elec-
trophoresis (2-D DIGE) followed by mass spectroscopy
analysis. We noticed that the transcripts and protein
level of GRP78 were significantly up-regulated in
enriched HN-CICs (Additional file 1 and Figure 1A).
To further validate the results from Affymatrix micro-
array and proteomic analyses, western blotting was
performed. Immunoblotting analyses showed that anti-
body against GRP78 detected more GRP78 protein in
crude cell extracts of enriched HN-CICs than in that
of parental HNSCCs (Figure 1B).
Recent findings of GRP78 on plasma membrane of
cancer cells but not on normal cells suggest that tar-
geted therapy against surface GRP78 of cancer cells may
be effective [24]. Compared to parental HNSCCs, we
found more membrane-associated GRP78 positive
(
memGRP78
+) cells in HN-CICs by FACS analyses (Fig-
ure 1C). In addition, it has been demonstrated that alde-
hyde dehydrogenase 1 (ALDH1) activity could be used
as a selection marker to isolated breast cancer CICs and
head and neck CICs [25,26]. Consistent with tumor
spheres formation ability, ALDH1
+ HNSCCs also dis-
played more
memGRP78
+ cells (Figure 1D). Finally, HN-
CICs showed elevated co-expression of either CD133 or
Cripto-1 with
memGRP78 in comparison to parental
HNSCCs (Figure 1E and 1F), where both CD133 and
Cripto-1, the well known CICs markers, have been used
to identify CICs [13,27,28]. Taken together, we hypothe-
s i z e dt h a tu p - r e g u l a t i o no fG R P 7 8 /
memGRP78 is pivotal
for maintenance cancer stemness characteristics of HN-
CICs.
memGRP78
+ HNSCCs display cancer initiating cells
properties in vitro and in vivo
To test whether
memGRP78
+ HNSCCs had the CICs
characteristics, SAS cells were sorted into
memGRP78
+
and
memGRP78
- cells by flow cytometry (Additional file
2A). Compared with
memGRP78
- SAS cells, the
memGRP78
+ SAS cells displayed higher levels of protein
and mRNA of stemness genes (Oct-4 and Nanog) (Fig-
ure 2A and Additional file 2B). We next performed
tumor spheres assay for evaluating the self-renewal abil-
ity of
memGRP78
+ and
memGRP78
- cells, respectively.
Interestingly,
memGRP78
+ cells had higher tumor
spheres-forming capability than
memGRP78
- HNSCCs
(Figure 2B). When isolated
memGRP78
+ and
memGRP78
-
cells were first cultivated within 10% serum for 10 days,
then the cell surface GRP78 expression profile was
further analyzed by flow cytometry, respectively. We
observed that
memGRP78
+ cells regenerated both
memGRP78
+ and
memGRP78
- cells, whereas,
memGRP78
+
cells were not detectable from cultivated
memGRP78
-
cells (Figure 2C). These data indicate that
memGRP78
+
HNSCCs could re-differentiate into
memGRP78
- cells. To
address whether the tumorigenic activity differed
between
memGRP78
+ and
memGRP78
- cells, in vitro
tumorigenic properties including matrigel invasion and
anchorage independent growth, and in vivo xenografts
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Page 2 of 16Figure 1 The differential expression of GRP78 and membrane associated GRP78 (
memGRP78) in parental HNSCCs and HN-CICs.( A) The
whole cell proteomes of SAS cells (Cy3-labled, green) and SAS-derived sphere cells (HN-CICs) (Cy5-labeled, red) were collected and analyzed by
two-dimensional differential gel electrophoresis (2-D DIGE). Image overlay of Cy3- and Cy5-labeled proteomes, red arrow indicates interests of
up-regulated. (B) Total proteins were prepared from parental HNSCCs (SAS and OECM1) or HN-CICs (SAS and OECM1-derived spheres) and
analyzed by immunoblotting with anti-GRP78 or anti-GAPDH antibodies as indicated. The amount of GAPDH protein of different crude cell
extracts was referred as loading control. (C)
memGRP78 positive cells expression in HNSCCs and HN-CICs was detected by FACS (**, p < 0.01;
***, p < 0.001). (D) The percentage of
memGRP78 positive cells in isolated ALDH1
+ and ALDH1
- HNSCCs, respectively. The co-expression profile
between
memGRP78 and Cripto-1 (E) or CD133 (F) in HNSCCs and HN-CICs was examined by FACS. (P: Parental HNSCCs; S: HNSCCs-isolated
sphere cells).
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Page 3 of 16Figure 2 Cancer stem cells properties of
memGRP78
+ and
memGRP78
- HNSCCs in vitro and in vivo. (A) Expressions of pluripotent stemness
genes (Oct4 and Nanog) in
memGRP78
+ and
memGRP78
- HNSCCs were determined by western analysis. The amount of GAPDH was referred as
loading control. (B) Representative images of tumorsphere-forming ability in
memGRP78
+ and
memGRP78
- HNSCCs grown under defined serum-
free selection medium as described at Materials and Methods. The numbers of spheres were further calculated using microscope. Results are
means ± SD from three experiments. (**, p < 0.01) (C) Sorted
memGRP78
+ and
memGRP78
- cells were further cultivated with standard medium
containing 10% serum. At day 10, the percentage of
memGRP78 expression was re-analyzed by flow cytometry. (D) To elucidate the anchorage
independent growth, single cells suspension of
memGRP78
+ and
memGRP78
- cells plated onto soft agar and analyzed. Results are means ± SD of
triplicate samples from three experiments (**, p < 0.01) (E) Invasion ability of
memGRP78
+ and
memGRP78
- cells were plated onto transwell coated
with matrigel and analyzed. Results are means ± SD of triplicate samples from three experiments (**, p < 0.01) (F) Increased radio-resistance
properties (OECM1-R3 > OECM1-R2 > OECM1-R1 > parental OECM1) positively correlates
memGRP78 expression in HNSCCs by FACS analysis.
(*, p < 0.05) (G) Summary of the in vivo tumor growth ability of different numbers of
memGRP78
+ and
memGRP78
- cells examined by
xenotransplantation analysis. (H) Representative tumor growth of
memGRP78
+ and
memGRP78
- HNSCCs was generated in the subcutaneous space
of recipient nude mice (Yellow arrows:
memGRP78
+ HNSCCs; Red arrows:
memGRP78
- HNSCCs). (I) Tumor volume was measured after inoculation
of
memGRP78
+ and
memGRP78
- HNSCCs in nude mice. Error bars correspond to SD (lower panel). (*, p < 0.05).
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Page 4 of 16assay were performed. The colony/invasion formation
abilities of
memGRP78
+ HNSCCs were significantly
higher than those of the
memGRP78
- HNSCCs (Figure
2D and 2E). To further evaluate the correlation between
memGRP78 expression profile and radioresistance, we
established radioresistant (R) HNSCCs (R1, R2, and R3)
by serially fractionated irradiation (see details from
Material and methods). We found that the expression
profile of
memGRP78 was significantly enhanced in
radioresistant HNSCCs (Figure 2F; R3>R2>R1>Parental
OECM1). For in vivo xenotransplantation assay, we
observed that 10000 GRP78
- cells did not induce tumor
formation but 100 GRP78
+ HNSCCs resulted in the
generation of visible tumors 4 weeks after injection in
xenotransplanted mice (Figure 2G, H, and 2I, Additional
file 2D, 2E and 2F). Collectively,
memGRP78 positive
cells possess the capabilities for self-renewal, differentia-
tion, radioresistance and high in vivo tumorigenicity.
Down-regulation of GRP78 reduces self-renwal properties
and inhibits tumorigenicity of HN-CICs
To further investigate the crucial role of GRP78 up-reg-
ulation in maintaining biological properties of HN-CICs
and HNSCCs, we performed the loss-of-function
approach to evaluate the effect of GRP78 knockdown on
HNSCCs derived HN-CICs. First, the HNSCCs derived
HN-CICs were generated by cultivating HNSCCs under
defined serum-free medium as described [13]. Then, the
enriched HN-CICs were infected with lentivirus expres-
sing either small hairpin RNA (shRNA) targeting GRP78
(shGRP78) or shRNA against luciferase (shLuc), respec-
tively. HN-CICs infected with shLuc lentivirus were
used as control cells. Successful infected HN-CICs was
validated as the Green Fluorescence Protein (GFP) posi-
tive cells since GFP was co-expressed as a reporter mar-
ker for cell transduction (data not shown). Western blot
analyses confirmed that both sh-GRP78-1 and sh-
GRP78-2 markedly repressed GRP78 protein expression
in both HN-CICs and HNSCCs (Figure 3A and Addi-
tional file 3A).
memGRP78
+ cells were also reduced in
shGRP78-expressing HN-CICs and HNSCCs (Figure 3B
and Additional file 3B). Differential levels of GRP78 sup-
pression between membrane and cytosol in head and
neck cancer initiating cells by western blotting and flow
cytometry results were examined in Additional file 3C.
Tumor-derived side population (SP) cells also have
been found to have characteristics of cancer stemness
[29].GRP78 depletion significantly decreased the side
population in HN-CICs and HNSCCs, respectively (Fig-
ure 3C and Additional file 3D). To further investigate
whether GRP78 expression plays a role in maintaining
self-renewal or cancer stem-like properties in HN-CICs
directly, the HNSCCs-derived tumor spheres, afterward
transduction with Sh-GRP78 lentivirus, did not maintain
floating spheres but show more attached epithelial-like
cells (Figure 3D). In opposite, HN-CICs after Sh-GRP78
lentiviruses infection displayed decreased expression of
“cancer stemness” genes (Oct-4, Nanog, and Nestin) but
enhanced expression of epithelial differentiation marker,
CK18 and Involucrin (Figure 3E and 3F). To determine
whether the reduction in tumor sphere formation effi-
ciency with GRP78 down-regulation is due to decreased
HN-CICs survival, we determined the percentage of
apoptotic cells using Annexin V staining. HN-CICs
transduced with Sh-GRP78 lentivirus significantly
increased the percentage of Annexin V-positive cells
(Figure 3G). Together, these results further support that
t h el o s so fG R P 7 8r e s u l t e di nad e c r e a s eo fC I C sp r o p -
erties due to up-regulation differentiation and apoptotic
activity.
To elucidate the direct effect of GRP78 knockdown on
in vitro tumorigenic properties including cell migration,
matrigel invasion and anchorage independent growth of
HN-CICs, single cell suspension of control- or GRP78-
knockdown HN-CICs were plated onto transwell cham-
ber (Figure 4A), onto transwell chamber coated with
matrigel (Figure 4B) or into soft agar (Figure 4C), and
analyzed as described in Materials and Methods, respec-
tively. The migratory/invasion/colony formation abilities
of GRP78 knockdown HN-CICs were significantly
reduced than those of the control HN-CICs (Figure 4A,
B, and 4C). We next sought to determine if down-regu-
lation of GRP78 expression could attenuate the tumor
initiating activity of HN-CICs in vivo. Strikingly,
GRP78-knockdown HN-CICs gave rise to a new tumor
at 5x10
5 in one of six mice, however, HN-CICs control
cells generated tumor when 1x10
4 cells were injected
into nude mice (three out of three mice)(Figure 4D). In
addition, knockdown of GRP78 expression in HN-CICs
and HNSCCs significantly reduced the tumor volumes
(Figure 4E and Additional file 3E). Overall, our data
indicate that down-regulation of GRP78 inhibited
in vitro tumorigenicity and in vivo tumor-initiating
activity of HN-CICs.
Overexpression of GRP78 in HNSSCs enhances in vitro
malignant potentials and
memGRP78
+ expression profile
To evaluate whether overexpression of GRP78 could
enhance tumorigenic properties of HNSCCs, we gener-
ated HNSCCs with transient overexpression of GRP78
by transfection with plasmids overexpressing GRP78
protein into HNSCCs. Total proteins from 293T cells or
HNSCCs (SAS) with transfection of GRP78 expressing
plasmids displayed elevated expression of GRP78 (Addi-
tional file 4A). Furthermore, we demonstrated that
GRP78 overexpression also resulted in increased ability
on in vitro cell migration (Additional file 4B). To evalu-
ate whether overexpressios of GRP78 on promoting
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Page 5 of 16Figure 3 Suppression of GRP78/
memGRP78 expression diminished spheres-forming capability, stemness genes expression, and side
population cells of HN-CICs. (A) Down-regulation of GRP78 in HN-CICs (SAS (left panel) and OECM1 (right panel) mediated by shRNAi was
validated by western blotting) (B) The percentages of
memGRP78
+ cells in sh-GRP78 knockdown and sh-Luc HN-CICs were compared by flow
cytometry analysis, respectively. (C) Single cell suspensions of sh-GRP78 and sh-Luc-expressing HN-CICs incubated with Hoechst 33342 were
examined for side population by flow cytometry. (D) HNSCCs-enriched sphere cells were first infected with Sh-GRP78-1, Sh-GRP78-2 or Sh-Luc
lentivirus, and further cultivated under the serum-free defined selection medium. The tumor sphere formation capability and cellular morphology
of enriched HN-CICs (Upper panel, SAS; Lower panel; OECM1) treated with either sh-Luc or GRP78-shRNA lentivirus were examined with
microscope. (E) Total proteins from figure 3d were isolated and immublotted by using antibodies against, anti-Oct-4, anti-Nanog, anti-Nestin or
anti-GAPDH antibodies as indicated. The amount of GAPDH protein of different crude cell extracts was referred as loading control. (F) Protein
level of epithelial specific differentiation markers, CK18 and invoclurin in enriched HN-CICs cells infected with sh-Luc, or sh-GRP78 lentivirus was
assessed by western blot. (G) Single cell suspension of spheres prepared from figure 3d transduced with sh-Luc or sh-GRP78 lentivirus were
stained with Annexin V and examined by flow cytometry. The experiments were repeated three times and representative results were shown.
Results are means ± SD (*, p < 0.05).
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Page 6 of 16Figure 4 GRP78 inhibition impaired in vitro and in vivo tumorigenic properties of HN-CICs. (A) To elucidate the capability of migration of
GRP78 shRNA knockdown and sh-Luc HN-CICs, single cell suspension of GRP78-specific shRNA or control sh-Luc HN-CICs were plated onto
transwell and analyzed as described in Materials and Methods. Results are means ± SD of triplicate samples from three experiments (**, p <
0.01). (B) Single cell suspension of GRP78-specific shRNA or control sh-Luc HN-CICs were plated onto transwell coated with matrigel and
analyzed as described in Materials and Methods. Data are means ± SD of triplicate samples from three experiments (**, p < 0.01; ***, p < 0.001).
(C) To elucidate the anchorage independent growth, single cell suspension of stable GRP78-specific shRNA or control sh-Luc HN-CICs (SAS
(upper panel), OECM1 (lower panel)) were plated onto soft agar and analyzed as described in Materials and Methods. Results are means ± SD of
triplicate samples from three experiments (*, p < 0.05; **, p < 0.01). (D) Summary of the in vivo tumor growth ability of different numbers of
GRP78-knockdown or control (sh-Luc) HN-CICs examined by xenotransplantation analysis. (E) Representative tumor growth of 10000 control and
10000 GRP78-knockdown HN-CICs was generated in the subcutaneous space of recipient mice (upper panels).Tumor volume was measured after
inoculation of GRP78-knockdown shRNA and sh-Luc-expressing HN-CICs (Yellow arrows: sh-Luc-expressing HNSCCs; Red arrows: sh-GRP78-
expressing HNSCCs) (lower panel). Error bars correspond to SD (*, p < 0.05; **, p < 0.01).
Wu et al. Molecular Cancer 2010, 9:283
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+ cells in HNSCC, SAS cells were co-trans-
fected with plasmids expressing green fluorescence pro-
tein (GFP) and GRP78. We discovered GFP positive
cells (meaning cells under successful transfection)
showed more
memGRP78
+ in co-transfected cells than
control cells (Additional file 4B). Together, our data
demonstrated that overexpression of GRP78 not only
enhanced in vitro malignancy but also expression profile
of
memGRP78
+ in HNSCCs.
Co-expression of GRP78 and Nanog in HNSCC tissues
We have been reported that HNSCC patients with
abundant Nanog protein expression are more likely to
have poor survival outcomes [13]. Overexpression of
GRP78 also correlates with poor HNSCC prognosis
[30]. To further investigate the correlation between
GRP78 and Nanog levels in human cancers, we estab-
lished the ontogeny of GRP78 and Nanog co-expres-
sion by tissue immunohistochemical staining with a
panel of specimens array of 46 HNSCC patients. Two
representative cases with double-positive or double-
negative of GRP78 and Nanog were shown in Figure
5A. We found co-expression of GRP78 and Nanog in
the moderate to poor-differentiated HNSCC tissues
rather than in well-differentiated HNSCC tissues (Fig-
ure 5A). The significant correlation between the
expression of GRP78 and Nanog in HNSCC tissues
was determined (Figure 5B, p < 0.05). To investigate
the prognostic significance of the expression GRP78
and Nanog patterns in HNSCC, we divided patients
into four groups: GRP78 (+)Nanog (+), GRP78 (+),
Nanog (+), and GRP78 (-)Nanog(-) HNSCC patients.
The Kaplan-Meier analyses showed that co-expression
of GRP78 and Nanog predicted the worse overall sur-
vival than all other HNSCC patients (Figure 5C).
GRP78 knockdown promotes apoptosis via survival
signaling in HN-CICs
To identify the systemic differential gene expression
profile by down-regulation of GRP78 in HN-CICs, we
performed Affymetrix microarray analyses. Upon the
knockdown of GRP78, we identified 434 probes consis-
tently induced or repressed and mapped them onto the
human PPIs. We filtered the mapped PPIs among the
differentially expressed genes by their co-expression of
the reactants in the GRP78-knockdown HN-CICs (PCCs
> 0.5). As shown in Figure 6A and 6B, 79 genes and 64
interactions were retained in the final networks. The
direction and strength of co-expression were depicted in
Figure 6B. Highly correlated genes were CTNNB1 v.s.
PTPN11, E2F1 v.s. CDC6, E2F1 v.s. RECQL, and MCM5
v.s. RPA2, with positive PCCs, as well as CHEK1 v.s.
E2F1, PSMA1 v.s. DLEU1, and HSPA8 v.s. NFKBIB,
with negative PCCs. Topologically, 24 inter-modular
hubs, 4 intra-modular hubs, and 51 periphery genes.
Functional annotation of the 79 genes in the networks
of GRP78 knockdown in HN-CICs was summarized in
Figure 6C. To further study the possible mechanisms
involved in GRP78-mediated cancer stemness properties,
we found out knockdown of GRP78 enhanced the
expression of PTEN, BAX and Caspase3 but reduced
the expression of p-MAPK in HN-CICs (Figure 6D).
These results support PTEN-PI3K-Akt and ERK signal-
ing is regard as crucial pathways in mediating CICs
characteristics [31,32]. Additionally, GRP78 might regu-
late survival pathways to modulate HN-CICs behaviors.
Discussion
The emerging importance of the stress response and
molecular chaperones in stem cells oncogenesis is well
recognized [33,34]. However, the relationship between a
stress-inducible endoplasmic reticulum chaperone and
cancer stem cells remains unclear. In this current study,
we first identified GRP78/
memGRP78, a stress-inducible
endoplasmic reticulum (ER) chaperone, was significantly
elevated in isolated HN-CICs through two-dimensional
differential gel electrophoresis or transcriptome profiling
analysis (Figure 1A and Additional file 1). Consequently,
GRP78
+ HNSCCs cells displayed CICs properties in
comparison to
memGRP78
- compartments (Figure 2).
We thus directly evaluated the functional role of GRP78
in the maintenance of stemness characteristics and
tumorigenic phenotype of HN-CICs. Lentiviral shRNA-
mediated knockdown of GRP78/
memGRP78 decreased
self-renewal ability, side population cells, stemness genes
expression in HN-CICs (Figure 3). Furthermore, analysis
of the cell survival and differentiation ability of
shGRP78-HN-CICs revealed that loss of GRP78 directly
caused a decrease of the CICs subpopulation due to
increasing of apoptotic and differentiated cells (Figure
3F and 3G). These results indicate that GRP78 directly
contributes to the self-renewal and survival of HN-CICs.
Increased tumorigenic activity is key hallmark of HN-
CICs, strikingly; we also found that knockdown of
GRP78 lessened tumor initiating activity of HN-CICs
both in vitro and in vivo ( F i g u r e4 ) .T h e s er e s u l t ss u g -
gest that elevated GRP78 signaling is associated with
stemness propeties and tumorigenic potentials of
HNSCCs.
It has been reported that GRP78 signaling is crucial
for cell survival/apoptosis via various apoptotic signaling
pathways [35,36]. In the ER membrane, GRP78 interacts
with caspase 7 and formed an antiapoptotic complex
[37]. Additionally, GRP78 it has been shown that GRP78
represses the activation of Bax and the release of cyto-
chrome C from the mitochondria. Overexpression of
GRP78 in glioblatomas cells renders these cells resistant
to etoposide- and cisplatin- induced apoptosis [38]. In
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Page 8 of 16Figure 5 Co-expression of GRP78 and Nanog in HNSCC tissues. (A) Representative pictures of double positive (left panel)a n dd o u b l e
negative (right panel) in 46 HNSCC patient cases. Magnification was shown at lower right corner. (B) Statistical analysis of correlation
betweenGRP78 and Nanog by Fisher extraction text. (C) Kaplan-Meier analysis of overall survival in HNSCC patients according to the expression
of GRP78 and Nanog (Group1: GRP78(+)Nanog(+), Group2: GRP78(+), Group3: Nanog (+) and Group4: GRP78 (-)Nanog(-)).(*, p < 0.05; **, p < 0.01;
***, p < 0.001).
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Page 9 of 16Figure 6 Differentially expressed genes in GRP78-knockdown HN-CICs. (A) A total of 79 significantly differentially expressed genes mapped
in the human PPIs were clustered (by row) according to their similarities in GRP78-knockdown HN-CICs, red indicating induction and blue
indicating repression. (B) Mapped human PPIs among the differentially expressed genes were grouped according to the topological
characteristics as highlighted in border colors (periphery: gray; inter-modular hubs: red; and intra-modular hubs: blue). Color legends were
according to expression patterns: as for nodes, red - induction and green - repression; as for edges, gray -negatively correlated and orange-
positively correlated. Thickness of edges was proportional to the absolute value of PCC and numbers indicated databases reporting such
interactions. (C) Top 4 functional annotation clusters analyzed from DAVID were listed. (D) Total proteins were prepared from Sh-Luc and Sh-
GRP78 expressing HN-CICs and analyzed by immunoblotting with antibodies against Caspase-3, BAX, PTEN, MAPK or GAPDH as indicated. The
amount of GAPDH protein of different crude cell extracts was referred as loading control.
Wu et al. Molecular Cancer 2010, 9:283
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Page 10 of 16contrast, knockdown of GRP78 decreases cell prolifera-
tion and sensitizes glioma cells to chemoradiotherapy
through the activation of caspase 7 cleavage [38].
GRP78 has also been implicated in proliferation proper-
ties through activation of the Akt pathways [39,40].
Recently, knockdown GRP78 or Cripto disrupts of the
Cripto binding to cell surface GRP78 in cancer cells
inhibits oncogenic signaling via MAPK/PI3K and
Smad2/3 pathways [41]. In accordance with other find-
ings, silencing of GRP78 increased BAX and Caspase3
but reduced the expression of p-MAPK in head and
neck cancer initiating cells (Figure 6). Collectively, our
data first demonstrated the crucial role of GRP78 in the
proliferation/apoptosis property of head and neck cancer
initiating cells.
Low oxygen tension or hypoxic condition plays an
important role in both the developing embryo and the
adult as specific niches [42]. Hypoxia is also a common
microenvironmental factor/niche that adversely influ-
ences tumor aggressiveness and treatment response [43].
Recently, many reports demonstrated hypoxia is also
crucial in maintaining the stem cells and CICs niche.
For example, hypoxia increases SP cells having high
tumorigenicity and CICs characteristics including Oct-4
up-regulation [44]. We also observed that HIF-1a was
up-regulated in our enriched HN-CICs (data not
shown). However, the hypoxia-inducible factors (HIFs)
function through the transcriptional regulation of a
number of important gene products [45]. Notably, it is
evident that HIF1a and HIF2a can often play non-over-
lapping biological roles due to their unique target genes.
HIF-1a promotes CD133-positive human glioma-derived
CICs propagation and self-renwal [46,47]. Whereas,
HIF-2a is an important primary regulator of hypoxic
responses, which shows strong tumor-promoting activity
and has been shown to bind to the Oct-4 promoter and
induce Oct-4 expression in ES cells [48]. Cellular adap-
tation to hypoxia occurs through multiple mechanisms,
including activation of the unfolded protein response
(UPR) in which GRP78 plays a crucial role [49,50].
Ostergaard and colleagues reveal that lowering O2,
probably in part through HIF, may upregulate the
expression of GRP78 [51]. Additionally, the elevation of
GRP78/
memGRP78 was also observed in HIF1a or
HIF2a-overexpressing HNSCCs (data not shown). Pre-
viously, we observed that enhanced expression of Oct-4,
Nanog and CD133 in our isolated HN-CICs [13]. More-
over, lentiviral knockdown of GRP78 expression
decreased stemness properties in HN-CICs. Based on
these findings, we proposed that HIF-mediated up-regu-
lation of GRP78 might provide HN-CICs with stemness
and tumorigenic properties.
In addition, Arnaudeau et al have demonstrated that
GRP78 directly interacts with P53 for stabilization and
inactivation in trophoblast and nasopharyngeal carci-
noma [52]. Lin et al report that P53 negatively regulates
the transcriptional activity of stem cell marker, Nanog
[53]. We also found that downregution of GRP78
reduced the Nanog expression in HN-CICs (Figure 3E).
Therefore, our current hypothesis is that the interaction
between GRP78 and p53 abrogates the negative regula-
tion of p53 on Nanog. However, future research deli-
neating the details of how GRP78 regulates its
downstream targets and how these interactions influ-
ence the stemness properties of CICs remain to be
determined.
Increased tumor initiating activity is hallmark of CSCs
[12]. Knockdown of GRP78 lessened tumor initiating
activity both in vitro and in vivo.H o w e v e r ,d e l e t i o no f
GRP78 did not completely eliminate and CICs proper-
ties tumor initiation potential of HN-CICs (Figure 4D).
It is reasonable that GRP78 signaling may not be the
only one pathway in contributing in the regulation of
HN-CICs, although, we and others observed that GRP78
regulates Wnt5A and PTEN-PI3K-Akt expression [54].
Other developmental signaling pathways, including
Notch, Hedgehog signaling and Bmi1 signaling have
been reported to play critical roles in the regulation of
various CICs characteristics, which were not significant
changed in GRP78-knockdown HN-CICs. Abnormal
functions and regulations of components of these signal-
ing pathways are often associated with different cancers,
implicating potential roles of these signaling pathways in
the CICs derived from different tissue origin. It would
be interesting to determine the potential cross-linking of
GRP78 signaling with other signaling pathways. These
studies also suggest that the use of a combination of
inhibitors for multiple signaling pathways might be
more effective than blockade of single pathway regulat-
ing HN-CICs.
Conclusions
Together, our present research shows that a novel path-
way, GRP78 signaling, plays a major role in the mainte-
nance of HN-CICs population. Targeting GRP78
signaling might be a potential therapeutic target for
HNSCC by eliminating HN-CICs. In addition, co-
expression of GRP78 and Nanog should be useful prog-
nostic factors for HNSCC patients.
Materials and methods
Cell lines cultivation and enrichment of HN-CICs from
HNSCCs
Originally, SAS was grown in DMEM, and OECM1 was
grown in RPMI supplemented with 10% fetal bovine
serum (FBS) (Grand Island, NY), respectively. The two
cell lines were then cultured in tumor sphere medium
consisting of serum-free DMEM/F12 medium (GIBCO),
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nant basic fibroblast growth factor-basic (FGF) and 10
ng/mL Epidermal Growth Factor (EGF) (R&D Systems,
Minneapolis, MN) (. Cells were plated at a density of
7.5 × 10
4 live cells/10-mm dish, and the medium was
changed every other day until the tumor sphere forma-
tion was observed in about 4 weeks [13].
RNA Isolation and Affymetrix GeneChip Analysis
RNA wasextracted from cells using Trizol reagent (Invi-
trogenLife Technologies), purity confirmed by
OD260:280 ratio and analyzed using formaldehyde gel
electrophoresis. For Affymetrix GeneChipanalysis,
RNAeasy kit (Qiagen, Valencia, CA) was used forfurther
RNA purification. Gene profiling was performedusing
Affymetrix Human Genome U133 plus 2.0 (containing
47,000 transcripts and variants, including 38,500 well-
characterized human genes) for the microarrays hybridi-
zation at the genomic core facilities at the National
Yang-Ming University Genome Research Center.
Construction of Lentiviral-mediated RNAi for silencing
GRP78
The pLV-RNAi vector was purchased from Biosettia Inc.
(Biosettia, San Diego, CA). The method of cloning the
double-stranded shRNA sequence is described in the
manufacturer’s protocol. Lentiviral vectors expressing
short hairpin RNA (shRNA) that targets human GRP78
(oligonucleotide sequence: Sh-GRP78-1:5’- AAAAGCC-
TAAATGTTATGAGGATCATTGGATCCAAT-
GATCCTCATAACATTTAGGC -3’;Sh-GRP78-2:5’-
AAAAGGAGCGCAUUGAUACUAGATTTTGGATC-
CAAAATCTAGTATCAATGCGCTCC-3’) were synthe-
sized and cloned into pLVRNAi to generate a lentiviral
expression vector. Lentivirus production was performed
by transfection of plasmid DNA mixture with lentivector
plus helper plasmids (VSVG and Gag-Pol) into 293T
cells using Lipofectamine 2000 (LF2000, Invitrogen,
Calsbad). Supernatants were collected 48 hours after
transfection and then were filtered; the viral titers were
then determined by FACS at 48 hours post-transduc-
tion. Subconfluent cells were infected with lentivirus in
the presence of 8 μg/ml polybrene (Sigma-Aldrich). The
GFP is expressed in lentivirus-infected cells as the mar-
ker to indicate that the cells express the shRNA for
silencing GRP78.
Aldefluor assay and flow cytometry
To measure and isolate cells with ALDH activity, the
Aldefluor assay was performed according to manufac-
turer’s (Stemcell Technologies, Durham, NC, USA)
guidelines. Dissociated single cells were suspended in
Aldefluor assay buffer containing the ALDH substrate,
Bodipy-aminoacetaldehyde (BAAA) at 1.5 mM and
incubated for 40 min at 37°C. To distinguish between
ALDH-positive and ALDH-negative cells, a fraction of
cells was incubated under identical condition in the pre-
sence of a 10-fold molar excess of the ALDH inhibitor,
diethylaminobenzaldehyde (DEAB). This results in a sig-
nificant decrease in the fluorescence intensity of ALDH-
positive cells and was usedt oc o m p e n s a t et h ef l o w
cytometer.
Side population analysis
Cells were resuspended at 1 × 10
6/mL in pre-warmed
DMEM with 2% FCS. Hoechst 33342 dye was added at
a final concentration of 5 μg/mL in the presence or
absence of verapmil (50 μM; Sigma) and was incubated
at 37°C for 90 min with intermittent shaking. At the
end of the incubation, the cells were washed with ice-
cold HBSS with 2% FCS and centrifuged down at 4°C,
and resuspended in ice-cold HBSS containing 2% FCS.
Propidium iodide at a final concentration of 2 μg/mL
was added to the cells to gate viable cells. The cells
were filtered through a 40-μm cell strainer to obtain sin-
gle cell suspension before analysis. The Hoechst 33342
dye was excited at 357 nm and its fluorescence was
dual-wavelength analyzed (blue, 402-446 nm; red, 650-
670 nm). Analyses were done on FACSAria (BD, San
Diego, CA).
Establish radiation resistant cell line
Cells were seeded on 75T flask at a density of 2 × 10
5 in
medium; kept culturing part of the cells for next radia-
tion treatment after ionizing irradiation and repeat three
times. The radiation resistant (R1, R2 and R3) cells were
for further experiments. The g-radiation (ionizing irra-
diation) was delivered by Theratronic cobalt unit T-
1000 (Theratronic International) at a dose rate of 1.1
Gy/min (SSD = 57.5 cm).
In vitro cell migration Assay
For transwell migration assays, 2 × 10
5 cells were plated
into the top chamber of a transwell (Corning, Acton,
MA) with a porous transparent polyethylene terephtha-
late membrane (8.0 μm pore size). Cells were plated in
medium with lower serum (0.5% FBS), and medium
supplemented with higher serum (10% FBS) was used as
a chemoattractant in the lower chamber. The cells were
incubated for 24 h and cells that did not migrate
through the pores were removed by a cotton swab.
Cells on the lower surface of the membrane were
stained with Hoechst 33258 (Sigma-Aldrich) to show
the nuclei; fluorescence was detected at a magnification
of 100× using a fluorescence microscope (Carl Zeiss,
Oberkochen, Germany). The number of fluorescent
cells in a total of five randomly selected fields was
counted.
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The 24-well plate Transwell® system with a polycarbo-
nate filter membrane of 8-μm pore size (Corning, Uni-
ted Kingdom) was employed to evaluate the invasion
ability of cells. The membrane was coated with Matri-
gel™ (BD Pharmingen, NJ, USA). The cancer cell suspen-
sions were seeded to the upper compartment of the
Transwell chamber at the cell density of 1 × 10
5 in 100
μl within serum-free medium. The lower chamber was
filled with media with 10% serum. After 24 hours of
incubation, the medium was removed and the filter
membrane was fixed with 4% formalin for 1 hour. Sub-
sequently, the remaining cells of the filter membrane
faced the lower chamber was stained with Hoechst
33258 (Sigma-Aldrich). The migrated cancer cells were
then visualized and counted from 5 different visual
areas of 100-fold magnification under an inverted
microscope.
Soft agar clonogenicity assay
Each well (35 mm) of a six-well culture dish was coated
with 2 ml bottom agar (Sigma-Aldrich) mixture
(DMEM, 10% (v/v) FCS, 0.6% (w/v) agar). After the bot-
tom layer was solidified, 2 ml top agar-medium mixture
(DMEM, 10% (v/v) FCS, 0.3% (w/v) agar) containing 10
4
cells were added, and the dishes were incubated at 37°C
for 4 weeks. Plates were stained with 0.005% Crystal
Violet then the colonies were counted. The number of
total colonies with a diameter = 100 μm was counted
over five fields per well for a total of 15 fields in tripli-
cate experiments.
Immunohistochemistry
Between 1994 and 1997, 46 consecutive patients with
operable head and neck cancer underwent surgery at
the Department of Oral and Maxillofacial Surgery,
Mackay Memorial Hospital. This research follows the
tenets of the Declaration of Helsinki and all samples
were obtained after informed consent from the patients.
None of the subjects received radiation therapy or che-
motherapy before surgery.Forty-six patients’ tissue sam-
ples with different stages of oral cancer were spotted on
glass slides for immunohistochemical stainings. After
deparaffinization and rehydration, the tissue sections
were processed with antigen retrieval by1X Trilogy
diluted in H2O (Biogenics) and heat. The slides were
immersed in 3% H2O2 for 10 minutes and washed with
PBS 3 times. The tissue sections were then blocked with
serum (Vestastain Elite ABC kit, Vector Laboratories,
Burlingame, CA) for 30 minutes, followed by incubating
with the primary antibody, anti-GRP78 (BD Transduc-
tion Laboratories™) in PBS solution at room temperature
for 2 hours in a container. Tissue slides were washed
with PBS and incubated with biotin-labeled secondary
antibody for 30 minutes and then incubated with strep-
tavidin-horse radish peroxidase conjugates for 30 min-
utes and washed with PBS 3 times. Afterwards, the
tissue sections were immersed with chromogen 3-3’-dia-
minobenzidine plus H2O2 substrate solution (Vector®
DBA/Ni substrate kit, SK-4100, Vector Laboratories,
Burlingame, CA) for 10 minutes. Hematoxylin was
applied for counter-staining (Sigma Chemical Co., USA).
Finally, the tumor sections were mounted with a cover
slide with Gurr® (BDH Laboratory Supplies, U.K.) and
examined under a microscope. Pathologists scoring the
immunohistochemistry were blinded to the clinical data.
The interpretation was done in five high-power views
for each slide, and 100 cells per view were counted for
analysis. (-, 0-10% positive cells; +, more than 10% posi-
tive cells)
Subcutaneous xenografts in nude mice
All the animal practices in this study were in accordance
with the institutional animal welfare guideline of
National Yang-Ming University, Taiwan. HNSCCs or
HN-CICs subject to treatment were injected subcuta-
neously into BALB/c nude mice (8 weeks). Tumor
volume (TV) was calculated using the following formula:
TV (mm3) = (Length × Width
2)/2 and then analyzed
using Image Pro-plus software.
Analyses of differential gene expression profiles, mapping
of human protein-protein interactions (PPIs), and
functional annotation clustering
All CEL files were pre-processed using method justRMA
and standardized with mean of zero and SD of 1. First,
modified t-test of the ‘limma’ package was used for dif-
ferential gene expression analysis between the control-
or GRP78-knockdown HN-CICs, controlled for FDR <
0.05 [55]. The analysis focused on precompiled calcium,
migratory [56,57] and stemness related gene lists
[58,59]. Second, we further filtered out differential
expression gene signatures with any inconsistent direc-
tion of regulation between any pair of control- v.s.
GRP78-knockdown HN-CICs. Third, differentially
expressed probes were mapped onto the human PPIs
downloaded from the NCBI Gene Portal (HPRD, Bio-
Grid, and BIND). PPIs would be retrieved if and only if
both of the interactants were listed as of those differen-
tially expressed. Fourth, absolute values of Pearson cor-
relation coefficients (PCCs) of the mapped PPIs were
calculated to identify cut-off threshold at 0.5 to filter
out possible false-positive interactions. Finally, network
topological analyses and classification of genes were per-
formed according to methods previously published [60].
Analytical computation, hierarchical clustering and heat-
map were performed and displayed using R statistical
software [61]. Functional enrichment clustering of genes
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DAVID (Database for Annotation Visualization and
Integrated Discovery, NIH) [62].
Transient overexpression of GRP78 in HNSCCs
To overexpress the GRP78 protein in HNSCCs, a plas-
mid (pCMV-GRP78; a gift from Dr. Ann-Joy Cheng,
Chang Gung University, Taipei, Taiwan) which can
overexpress the GRP78 in mammalian cells under CMV
promoter, was introduced HNSCCs transiently by trans-
fection. In the meanwhile, plasmids encoding green
fluorescence protein were co-introduced into host cells
to identify the successful transfection cells.
Statistical analysis
The independent Student’s t-test was used to compare
the continuous variables between groups, whereas the
c
2 test was applied for the comparison of dichotomous
variable. Statistical Package of Social Sciences software
(version 13.0) (SPSS, Inc., Chicago, IL) was used for sta-
tistical Kaplan-Meier analysis. The Kaplan-Meier esti-
mate was used for survival analysis, and the log-rank
test was selected to compare the cumulative survival
durations in different patient groups. The level of statis-
tical significance was set at 0.05 for all tests.
Additional material
Additional file 1: Clustering the progressive gene expression
profiles of in the HN-CICs. The heat maps of the transcripts
differentially expressed in parental HNSCCs and HNSCCs-derived HN-CICs.
Red arrows indicate GRP78.
Additional file 2: Cancer stemness properties of
memGRP78
+ and
memGRP78
- HNSCCs. (A) Sorted
memGRP78
+ and
memGRP78
- HNSCCs by
flow cytometry. (B) Total RNA was purified from parental
memGRP78
+ and
memGRP78
- HNSCCs, and the expression of stemness transcript (Oct4 and
Nanog) was detected by and RT-PCR analysis. (C)
memGRP78
+ and
memGRP78
- cells plated onto soft agar and analyzed colony size. In vivo
tumor growth ability of 5 × 10
5 (D) and 1 × 10
5 (E)
memGRP78
+ and
memGRP78
- cells examined by xenotransplantation analysis. (F)
Representative tumor growth of
memGRP78
+ and
memGRP78
- HNSCCs was
generated in the subcutaneous space of recipient nude mice (Yellow
arrows:
memGRP78
+ HNSCCs; Red arrows:
memGRP78
- HNSCCs).
Additional file 3: Depletion of GRP78 impairs in vitro tumorigenic
properties of HNSCCs and HN-CICs. (A) Down-regulation of GRP78 in
HNSCCs (SAS (left panel) and OECM1 (right panel) mediated by shRNAi
was validated by western blotting. (B) The percentages of
memGRP78
+
cells in sh-GRP78 knockdown and sh-Luc HN-CICs were compared by
flow cytometry analysis, respectively. (C) Differential levels of GRP78
suppression between membrane and cytosol regions in head and neck
cancer initiating cells (SAS and OECM1) were examined by western
blotting and flow cytometry results. (D) Single cell suspensions of sh-
GRP78 and sh-Luc-expressing HNSCCs incubated with Hoechst 33342
were examined for side population by flow cytometry. (E) Tumor volume
was measured after inoculation of GRP78-knockdown shRNA and sh-Luc-
expressing cells. Error bars correspond to SD.
Additional file 4: Overexpression of GRP78 modulates expression of
tumorigenic potentials of HNSSCs. (A) Total proteins were prepared
from control (Vector alone) and GRP78-overexpressing host cells (left,
293T and right: SAS) and analyzed by immunoblotting against anti-
GRP78, or anti-GAPDH antibodies as indicated. (B) To elucidate the
capability of migration of GRP78-overexpressing and control HNSCCs
(SAS and OECM1), single cell suspension of GRP78-overexpressing or
control HNSCCs were plated onto transwell and analyzed as described in
Materials and Methods. Results are means ± SD of triplicate samples
from three experiments. (C) SAS cells were transfected with GFP and/or
GRP78 (GRP78
over) overexpressing plasmids. The expression profile of GFP
and
memGRP78
+ cells were further examined by FACS analyses.
Representative images were displayed (left panel). The percentages of
memGRP78
+ cells from each experimental group were calculated using
GFP positive cells as 100% successful transfection rate. Results are means
± SD of triplicate samples from three representative experiments. (*, p <
0.05; ***, p < 0.001).
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